Clinical Summary: Real-World Implementation of Xanomeline-Trospium in Schizophrenia: A Consensus Panel Report
Patients with schizophrenia often need lifelong treatment, yet standard dopamine-blocking antipsychotics leave many with persistent negative or cognitive symptoms and accumulate burdens such as EPS, metabolic effects, and prolactin elevation. This report addresses how clinicians can actually start, titrate, and combine xanomeline-trospium in practice while managing the early gastrointestinal and anticholinergic issues that most affect adherence.
Key Findings
- In the pooled 5-week EMERGENT 1–3 studies, discontinuation rates were similar between groups (27.6% XT vs 22.7% placebo), while treatment-emergent adverse events were more common with XT (67.9% vs 51.3%), largely gastrointestinal in nature and generally mild or moderate.
- In EMERGENT-4, improvements in PANSS total score with XT were sustained through week 52, with 68.6% of participants achieving ≥30% improvement and 37.1% achieving ≥50% improvement from baseline.
- By week 52 in EMERGENT-4, CGI-S improvements of at least 1 point were observed in 82.9% of the overall population, and 42.9% achieved CGI-S scores ≤3.
- In EMERGENT-4, 53% of participants experienced at least 1 treatment-emergent adverse event; the most frequent anticholinergic events were dry mouth (17.8%), constipation (9.9%), and dyspepsia (8.6%), while common procholinergic events included nausea (10.5%), vomiting (6.6%), and diarrhea (5.9%).
- In a retrospective analysis of 49 hospitalized patients with chronic, treatment-resistant psychotic disorders, approximately half demonstrated clinically meaningful improvement following initiation of XT.
XT adds a non–dopamine-blocking option for schizophrenia that can be used early, during inpatient stabilization, or during antipsychotic cross-titration, with the main implementation challenge being front-loaded gastrointestinal and anticholinergic tolerability. In practice, success depends on fasted dosing, medication reconciliation, structured tapering of existing antipsychotics, and proactive antiemetic support.
Practice Implications
- Start outpatient XT at 50 mg/20 mg twice daily for 1 to 2 weeks, then titrate based on symptom response and tolerability; many patients stabilize on 100 mg/20 mg–125 mg/30 mg twice daily.
- Prescribe ondansetron 4 mg for the first 14 days at initiation, with instructions to re-dose after 30 minutes if symptoms persist, to reduce nausea- and vomiting-related early discontinuation.
- Counsel patients to take XT on an empty stomach because food can interfere with trospium chloride absorption and increase the likelihood of gastrointestinal side effects.
- Before initiating XT, reduce unnecessary anticholinergic burden and review medications for sleep, bladder control, COPD, Alzheimer’s disease, and Parkinson’s disease; monitor specifically for urinary retention, dry mouth, and constipation.
